Equity Insider News Commentary 

AUSTIN, Texas, Oct. 1, 2026 /CNW/ — Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth rate of 23.22%. Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (NASDAQ: HYFT), AbCellera Biologics Inc. (NASDAQ: ABCL), Eli Lilly and Company (NYSE: LLY), Twist Bioscience Corporation (NASDAQ: TWST) and Tempus AI, Inc. (NASDAQ: TEM).

Other forecasters size the market differently but point the same way. Grand View Research projects the AI drug discovery market will grow from $2.9 billion in 2026 to $13.8 billion by 2033, a compound annual growth rate of 24.8%. Global Market Insights projects growth from $4.0 billion in 2026 to $43.9 billion by 2035, a compound annual growth rate of 30.5%, citing generative AI, predictive analytics and multi-omics data as drivers.

The spread between those estimates is wide, which is a reminder that these are third-party projections for an industry as a whole, built on different definitions of what counts as AI drug discovery. They are not addressable revenue for any company named here.

What the forecasts share is a view that the work is moving from experiments to deployed infrastructure. Public companies in the group are reporting software contracts, data-licensing agreements, financings and clinical-trial plans rather than only research milestones, and several of those developments landed in the past few weeks.

That shift raises a practical question for investors. As AI platforms are applied to regulated life sciences workloads, data integrity and governance become part of what a company is selling, and the people overseeing the company matter more. A board appointment announced this week from Austin, Texas, speaks to that point directly.

MindWalk Holdings Corp. (NASDAQ: HYFT) Appoints Kim Remizowski, Veteran Banker and Licensed Fiduciary, to Board of Directors as Independent Director

Appointed as an independent director, to serve on the Audit Committee and the Governance, Nomination and Compensation CommitteeThe Board has determined that he qualifies as an independent director under Nasdaq listing rules and as an audit committee financial expert under applicable SEC rules35 years of experience in institutional banking and fiduciary oversightMost recently Director, Private Equity at Vistra, a global corporate services group operating in more than 50 jurisdictionsPrior roles include board service at Merrill Lynch Bank and Trust Company (Cayman) Ltd., Managing Director at DMS Bank & Trust Ltd., and 17 years at Royal Bank of CanadaAccredited Director of the Chartered Governance Institute of Canada and a Licensed Director with the Cayman Islands Monetary Authority

MindWalk Holdings Corp. (“MindWalk”), a Bio-Native AI company, announced the appointment of Kim Remizowski to its Board of Directors as an independent director. Mr. Remizowski will serve on the Audit Committee and the Governance, Nomination and Compensation Committee. The Board has determined that he qualifies as an independent director under Nasdaq listing rules and as an audit committee financial expert under applicable SEC rules.

Mr. Remizowski most recently served as Director, Private Equity at Vistra, where he oversaw governance for a portfolio of investment funds and holding structures and worked across a network of fund sponsors, institutional allocators and family offices in North America, Europe, Latin America and the Caribbean. According to MindWalk, he previously served as Resident Director on the Board of Directors of Merrill Lynch Bank and Trust Company (Cayman) Ltd., a Class B licensed bank, with governance, regulatory and statutory reporting responsibility across the bank’s loan, deposit and investment businesses, and as Managing Director of DMS Bank & Trust Ltd., with responsibility for the bank’s strategic direction, operations, finance and compliance. He also led the Private Client Trust & Corporate team at Intertrust Group (now CSC), and began his career at Royal Bank of Canada, where over 17 years he advanced through branch management, inspection and operations roles to regional responsibility for 13 branches.

He is a Trust and Estate Practitioner with STEP, an Associate of the Institute of Canadian Bankers and a Certified Digital Asset Advisor, and maintains an active professional interest in the governance of emerging technologies, including artificial intelligence and digital assets.

MindWalk says the appointment comes as it expands contracted, recurring platform deployments with life sciences clients on ReefIQ™, the biological context layer for life sciences, powered by HYFT® Technology. In the Company’s words, serving regulated life sciences workloads puts data integrity and governance at the center of its value proposition and raises the premium on independent financial and governance oversight at the Board level.

“Kim brings the kind of governance depth that becomes load-bearing exactly when a company moves from building technology to deploying it at scale,” said Jennifer Bath, PhD, President and Chief Executive Officer of MindWalk. “We are selling infrastructure into regulated life sciences workloads, and the credibility of that position rests as much on the quality of our governance as on the quality of the science. Kim has spent 35 years inside regulated financial institutions as a bank director and licensed fiduciary, and he brings that governance discipline to our Board and its committees. We are pleased to welcome him to the Board.”

“MindWalk is building foundational infrastructure for life sciences AI and holding itself accountable for how that infrastructure is governed. That is a discipline I recognize from the institutional side of finance,” said Mr. Remizowski. “I look forward to working with Dr. Bath, the Chair, and my fellow directors, and to bringing the rigor of regulated financial oversight to the Board’s committees as the Company scales.”

MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require, integrating AI, data and advanced wet lab capabilities into one connected discovery ecosystem. At its core is HYFT® Technology, a proprietary, function-aware representation of biology. Its HYFT fingerprints span sequence and structural biology and, refined over 20 years of curation, form a continuously evolving biological representation of 660 million patterns and 25 billion relationships. This representation is the architecture behind ReefIQ™, the biological context layer that enriches data at ingestion and grows more valuable with each program run on it, and LensAI™, the reasoning and application layer for target discovery, candidate diligence, portfolio decision support and the agentic AI workflows pharma is racing to deploy. By design, value compounds in the HYFT representation layer, not in any individual AI model that runs on top of it.

There are several risks associated with the Company’s plans. A board appointment does not by itself produce customers, contracts or revenue, and the ability of a newly appointed director to contribute to governance, oversight and strategic direction as anticipated is not assured. MindWalk’s risks include maintaining compliance with Nasdaq listing standards, converting engagement into contracted, recurring platform arrangements and retaining and expanding them, building out the compliance and governance capabilities required for regulated life sciences workloads, market acceptance of ReefIQ and LensAI, intellectual property risks, competition, and capital markets and economic conditions. Investors should review MindWalk’s Annual Report on Form 20-F and other filings on SEDAR+ at sedarplus.ca and on EDGAR at sec.gov/edgar.

Read this and more news for the sector at: equity-insider.com

There’s many other industry developments and happenings in the market this week including:

AbCellera Biologics Inc. (NASDAQ: ABCL)

AbCellera runs an antibody discovery engine that has moved toward developing its own clinical-stage programs, which makes it the closest public analogue to the discovery-plus-pipeline model MindWalk describes, though at far greater scale. On Aug. 10 the company reported positive top-line results from the Phase 2 portion of its Phase 1/2 trial of ABCL635, an investigational neurokinin 3 receptor antagonist antibody being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomotor symptoms due to menopause. The study met its primary endpoints, with a single dose reducing the frequency and severity of hot flashes at week 4 compared to placebo. The company has said it will present additional Phase 2 data at the IMS World Congress on Menopause, which runs Sept. 30 to Oct. 3.

The balance sheet strengthened alongside the data. AbCellera reported over $565 million in total cash balances and marketable securities as of the second quarter, with $110 million in non-dilutive government funding available, and its June 2026 collaboration with Jazz Pharmaceuticals plc and July 2026 collaboration with Vertex Pharmaceuticals Incorporated together add more than $100 million in upfront cash. “Since our last business update we signed two new collaborations, one with Jazz and one with Vertex, that leverage our T-cell engager platform to advance programs into the clinic,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. AbCellera is substantially larger and better capitalized than MindWalk and remains loss-making, which is the normal condition for platform companies moving into asset development.

Pfizer Inc.

Pfizer sits on the demand side of this market, and the way it has chosen to buy AI capability speaks directly to where differentiation is moving. On Jan. 8, 2026 the company announced a strategic collaboration with Boltz, PBC to put biomolecular AI foundation models and generative workflows in the hands of its scientists for small-molecule and biologics design. Boltz’s models, Boltz-2 and BoltzGen, are open source and already widely used across the industry for protein design, biomolecular structure prediction and affinity estimation.

The structure of the arrangement is the instructive part. Under the collaboration Boltz will refine its foundation models on Pfizer’s own historical data to produce exclusive models for structure prediction, small-molecule affinity and biologics design, with Boltz scientists working alongside Pfizer discovery teams, and Pfizer retains full ownership of compounds discovered or developed using them. A company with one of the deepest data estates in the industry licensed an open model and then differentiated it with proprietary data rather than betting on the model itself. That is the same structural argument MindWalk makes for its own layer, reached independently and at an entirely different scale. Pfizer is referenced as demand-side context only.

Eli Lilly and Company (NYSE: LLY)

Eli Lilly has been among the most active buyers of AI-enabled discovery capability, and in 2026 it began packaging its own data as a platform for others to build on. On Sept. 16 both Twist Bioscience Corporation (NASDAQ: TWST) and Ginkgo Bioworks Holdings, Inc. announced agreements with Lilly TuneLab, a collaborative drug discovery platform established by Lilly that gives participating companies access to AI and machine-learning models trained on Lilly-owned research data.

The division of labor in those agreements is worth noting. The models come from the pharmaceutical company; the data that makes them useful is supplied by specialists, with Twist contributing antibody characterization data and Ginkgo contributing discovery data generation through its Ginkgo Datapoints offering. Lilly also took a $40 million strategic equity position in Absci Corporation’s approximately $100 million June 2026 financing. Lilly and Ginkgo are referenced as market and sector context and are not comparables of the profiled company.

Twist Bioscience Corporation (NASDAQ: TWST)

Twist sits a layer further down the stack, manufacturing synthetic DNA and next-generation sequencing tools that the discovery industry consumes as raw input, and it is now selling data services into pharma-owned AI platforms as well. In May 2025 it revised its DNA supply collaboration with Ginkgo Bioworks. Its TuneLab role, supplying antibody characterization data to companies running Lilly-trained models, places it adjacent to the antibody-discovery work MindWalk’s platform is built around.

The operating numbers have been moving in the right direction. Twist reported third quarter fiscal 2026 revenue of $118.4 million, growth of more than 23% year over year and its fourteenth consecutive quarter of growth, with gross margin of 52.8% against 51.6% in the prior quarter, and NGS Applications revenue up 12% to $61.8 million. The company raised full-year fiscal 2026 revenue guidance to a range of $456 million to $457 million and reiterated its expectation of reaching adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. “That milestone is not the destination. It’s the foundation for delivering disciplined execution and profitable growth as we move through fiscal 2027,” said Chief Executive Officer and co-founder Emily M. Leproust. Twist is a picks-and-shovels supplier rather than a software company, and is substantially larger than MindWalk.

Tempus AI, Inc. (NASDAQ: TEM)

Tempus is the scaled public proof of the argument that pharmaceutical customers will pay for curated data rather than for models, selling precision-medicine diagnostics alongside a data-licensing business that supplies clinical and molecular data to drug developers. On Sept. 11 it launched an effort to build a multimodal whole-genome dataset, beginning with 100,000 disease-specific genomes linked to longitudinal clinical outcomes and with an aspiration to reach 1 million, available now through an Early Adopter Program with general availability planned for mid-2027. “A large dataset is only valuable if you can turn it into insight,” said founder and chief executive officer Eric Lefkofsky.

Ten days later Tempus extended its data license agreement with Recursion Pharmaceuticals, Inc., a collaboration dating to 2023, through November 2029, replacing discretionary fees that could have totaled $84 million over two years with committed payments of $42 million over three years, and separately licensing Recursion’s proprietary RNA sequencing foundation model, TxFM, under a non-exclusive worldwide license. “We are thrilled to extend our collaboration with Recursion beyond the initial committed period, demonstrating the ongoing value of this partnership,” said Ryan Fukushima, chief executive officer of Data and Apps at Tempus. The renewal is the instructive part. A data license that gets extended and put on committed terms rather than allowed to lapse is what a durable data asset looks like from the outside, and it is the economic pattern MindWalk is arguing for one layer down, at discovery. Tempus operates at a scale entirely different from the profiled company and is referenced as sector context only.

Contact Information: equity-insider.com
Media Contact: info@equity-insider.com

DISCLAIMER

Nothing in this publication should be considered personalized financial advice. We are not licensed under securities laws to address your particular financial situation, and no communication from us should be deemed personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

This article is being distributed for Market Equities Limited, a company incorporated under the laws of Ireland (“MEL”), which wholly owns and operates Equity Insider. MEL has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group (“CDMG”). MEL also expects to receive further compensation as part of an ongoing digital media effort to increase visibility for the company. No further notice will be given, but let this disclaimer serve as notice that all material, including this article, has been reviewed and approved by MindWalk Holdings Corp. and CDMG.

This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged not to use this publication as the basis for any investment decision.

MEL and its owners, operators, directors, and affiliates do not own any shares of MindWalk Holdings Corp., but reserve the right to buy and sell shares of MindWalk Holdings Corp. at any time without further notice, commencing immediately and ongoing, in the open market, through private placements, and/or through other investment vehicles. There may also be third parties who hold shares of MindWalk Holdings Corp. and may liquidate their shares, which could have a negative effect on the price of the stock.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful. Investing in securities carries a high degree of risk, and you may lose some or all of your investment.

Cautionary Note Regarding Company Statements. Statements in this article about MindWalk Holdings Corp., its board appointment, its platform and its customer arrangements are drawn from the Company’s own announcement and have not been independently verified by us. A board appointment does not indicate future results, and nothing in this article states or implies that it will lead to customer contracts, revenue or profitability. Statements about the Company’s contracted, recurring platform deployments are the Company’s, and the Company has not identified customers, deployment counts or contract values. Market-size figures are third-party projections of an industry as a whole, not addressable revenue for MindWalk or any company named here. Investors should review MindWalk’s Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar).

Referenced Companies. References to AbCellera Biologics Inc. (NASDAQ: ABCL), Pfizer Inc., Eli Lilly and Company (NYSE: LLY), Twist Bioscience Corporation (NASDAQ: TWST), Ginkgo Bioworks Holdings, Inc., Tempus AI, Inc. (NASDAQ: TEM), Recursion Pharmaceuticals, Inc., Absci Corporation, Jazz Pharmaceuticals plc, Vertex Pharmaceuticals Incorporated and Boltz, PBC are provided solely as market and sector context. Those companies are not peers, competitors or financial comparables of MindWalk Holdings Corp., differ substantially from it in size, stage, capitalization and business model, are not involved in the preparation of this article, and their results, financings, collaborations and share performance are not indicative of MindWalk’s prospects. Nothing in this article states or implies any commercial relationship, partnership, affiliation or endorsement between MindWalk Holdings Corp. and any of them. Market-size figures are third-party projections of an industry as a whole, not addressable revenue for MindWalk or any company named here.

Trademarks. HYFT® is a registered trademark of MindWalk Holdings Corp. ReefIQ™ and LensAI™ are trademarks of MindWalk Holdings Corp.; ReefIQ™ registration is pending. All other marks referenced in this article are the property of their respective owners.

Eagle Eye Disclosure. Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided on the platform is for informational purposes only and may be delayed. Always do your own research before making any investment decision.

Cautionary Note Regarding Forward-Looking Statements. This article contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements about market forecasts, platform deployment, commercialization, product development and the contribution of newly appointed directors. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers should not place undue reliance on them, and we undertake no obligation to update them except as required by law.

This document is governed by the laws of Ireland.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-drug-discovery-forecasts-vary-widely-as-sector-shifts-to-deployment-302896260.html

SOURCE Equity Insider